Participated · Series B · Aug 2026

InduPro uses a proprietary proximity-guided platform to map spatial organization of proteins on the cell surface and discover selective co-target pairs for therapeutic development. Its lead program, IDP-001, is a potential first-in-class proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen (TAPA-E1). IDP-001 was designed to enhance tumor selectivity, target internalization, and antitumor efficacy while aiming to preserve tolerability, and the first patient has been dosed in its Phase 1 study. The Phase 1 trial is enrolling adults with advanced or metastatic squamous and non-squamous non-small cell lung cancer and other squamous solid tumors to evaluate safety, pharmacokinetics and preliminary antitumor activity. Beyond ADCs, InduPro is developing bispecific antibodies including antibody-drug conjugates and T-cell engagers to build a pipeline of first- and best-in-class programs. The company operates out of Seattle and Cambridge, Mass., and is advancing both clinical and preclinical programs supported by venture and strategic pharma investors.

Participated · Equity · Sep 2025

Ensoma is a Boston-based biotechnology company focused on engineering hematopoietic stem cells directly inside the body to create durable genetic medicines for genetic diseases, immune disorders, and cancer. Its platform uses high-capacity virus-like particles (VLPs) that selectively target HSCs and can deliver up to 35 kb of genetic cargo, enabling single-base edits through large multi-gene insertions. The company combines these VLPs with proprietary base-editing and gene-integration systems, aiming for one-time intravenous administration. Proceeds from its latest financing will fund a Phase 1/2 clinical trial of lead candidate EN-374 for X-linked chronic granulomatous disease and support platform expansion into immuno-oncology and sickle cell programs. Ensoma’s strategy centers on creating off-the-shelf, non-myeloablative treatments that avoid the complexity and cost of ex vivo cell processing. The firm’s board now includes a Gilead appointee following the strategic investment. No financial metrics or commercial revenues have been disclosed to date.

Participated · Series A · Mar 2025

Maxion Therapeutics is developing antibody-based KnotBody therapeutics that combine naturally occurring mini-proteins (‘knottins’) with antibodies using phage and mammalian display technologies. The company is building a pipeline targeting ion channel- and GPCR-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease. Its lead programme is MAX001, and Maxion intends to advance this asset toward clinical proof-of-concept. The company plans to use the newly raised capital to accelerate its expansion into a clinical-stage biotech and to progress additional programmes toward the clinic. Maxion was founded in 2020 by Dr John McCafferty and Dr Aneesh Karatt-Vellatt and is led by CEO Arndt Schottelius. It raised $72M in a Series A to fund these clinical development plans. Maxion Therapeutics applies its patented KnotBody platform to create antibody-like therapeutics by fusing cysteine-rich miniprotein 'knottins' onto antibodies to modulate ion channels and GPCRs. The KnotBody design aims to combine ion-channel blocking activity with the long half-life and engineerability of antibodies. Maxion's early R&D has produced KnotBodies against ion channel targets implicated in autoimmune disease, a target class with no antibody-based drugs currently approved or in clinical development. The company intends to use recent funding to advance, expand and optimise its pipeline and to progress the most promising candidates toward clinical trials for autoimmune indications and chronic pain. Financially, Maxion was awarded a £2 million Innovate UK grant and in February 2023 completed a £13 million Series A financing led by LifeArc Ventures, with Monograph Capital and BGF as equal participants. Maxion is based at the Babraham Institute in Cambridge and is led by CEO and co-founder Dr John McCafferty and CSO and co-founder Dr Aneesh Karatt Vellatt. Maxiom Therapeutics develops biologic medicines that target ion channels and G-protein-coupled receptors (GPCRs), addressing diseases including autoimmune conditions and chronic pain. It applies a patented KnotBody platform that fuses cysteine-rich knottin miniproteins onto antibodies to combine knottins' functional activity with the drug-like properties of antibodies. The company says early R&D has yielded KnotBodies against several therapeutically relevant targets, which it intends to develop as selective, long-acting first‑in‑class and best‑in‑class therapeutics. Maxiom will use the Series A proceeds to advance development of antibody drugs against ion channels and GPCRs. The company is led by CEO and co‑founder Dr John McCafferty and CSO and co‑founder Dr Aneesh Karatt Vellatt. Maxiom is based in Cambridge, UK.

Participated · Series A · Oct 2024

Axonis is developing first-in-class oral small molecules that potentiate KCC2, a CNS chloride transporter crucial for inhibitory neurotransmission. Its lead candidate, AXN-027, is designed to restore functional inhibition and is being advanced into clinical proof-of-concept in patients with epilepsy and pain. The company plans to use its proprietary KCC2 discovery engine to develop next-generation compounds for additional indications including psychiatric and neurodevelopmental disorders. Axonis was spun out from Boston Children’s Hospital, Harvard and Université Laval and is headquartered in Boston, MA. Leadership includes co-founder and CEO Joanna Stanicka, Ph.D., CSO Shane Hegarty, Ph.D., and new appointments for Chief Medical Officer Donald Manning, M.D., Ph.D., and COO Jeff Imbaro. The company has received grant support from multiple public and non-profit sources and will use the recent financing to fund clinical development and pipeline expansion. AXONIS Therapeutics is an emerging biotechnology company based in Cambridge, MA, advancing neuromodulating therapies for central nervous system disorders. Its pipeline focuses on neuron-reviving approaches that enable CNS neurons to resist degeneration, restore excitation/inhibition balance, and regenerate. The company’s primary program centers on upmodulation of the KCC2 protein and has completed proof-of-concept preclinical studies showing reactivation of spared neural tissue at sites of spinal cord injury. Targeted indications include spinal cord injury and epilepsy, with potential applicability to chronic pain, Rett syndrome and broader neurodegenerative conditions. AXONIS has licensed three technologies, including recently discovered methods to prevent neurodegeneration, and is investigating additional methodologies to revive neurons. Financially, the company secured $4 million in seed funding at its operational launch in early 2020, has received non-dilutive awards from the Massachusetts Life Sciences Center and NIH SBIR and two Golden Tickets from Boehringer Ingelheim and Astellas, and just raised additional financing to support clinical advancement and IND-enabling activities. AXONIS Therapeutics is advancing a novel KCC2 upmodulation therapy to reactivate spared neural tissue after spinal cord injury and is also investigating PTEN inhibition to regenerate injured nerve connections. The company has licensed or optioned two technologies from Boston Children’s Hospital to support its preclinical programs. Proceeds from the current financing will enable AXONIS to conduct preclinical studies and expand its team as it moves toward proof-of-concept milestones. AXONIS reports promising proof-of-concept results to date and expects to deliver additional proof-of-concept data in approximately one year. The company has received state and federal non-dilutive funding and other seed investment, and won a Boehringer Ingelheim Golden Ticket that provides one year of free lab space at LabCentral. Leadership includes CEO Joanna Stanicka, PhD, Executive Chair and co-founder Corey Goodman, PhD, and founder Bob Yant; the company is based in Cambridge, MA.

Participated · Equity · Dec 2023

EvolveImmune develops immuno-oncology biologics that provide sustained immune activation while directly targeting tumor cells within a single drug. The company integrates signaling to enable its EVs platform to directly target tumor cells and amplify localized cytokine secretion at tumor sites. Its approach is designed to provide tissue-localized cytokine amplification to maximize tumor cell killing. EvolveImmune positions its EVs as the first biologic to directly target tumor cells and deliver focused cytokine effects in the tumor microenvironment. The article reports the company completed a $37 million financing round, indicating external investor support for its technology. No operating metrics such as revenue or user counts are provided in the article.